Chimeric antigen receptor (CAR) T cell therapy targeting CA19-9, an antigen over-expressed in several cancers, including 80-90% of pancreatic cancers.
Targeted delivery of an anti-inflammatory cytokine to prevent heart failure after myocardial infarction.
An open-top microfluidic chip enables transplantation of human solid tumor explants into vascularized 3D tissue for controlled CAR-T perfusion, imaging, and analysis.
Using tiny lipid nanoparticles (LNPs) to improve mRNA medicine delivery and uptake in the placenta for healthier pregnancies
Microfluidic device for generation of large, precisely-defined, diverse lipid nanoparticle libraries for screening LNP formulations.
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis.
Antigen-specific immunotherapy with engineered cytotoxic T cells targeting misformed proteins to treat neurodegenerative and muscular diseases.
A Switchable Bispecific T-Cell Nanoengager (sBiTNE) to link T cells with cancer cells that can be reversed if off-tumor toxicity is detected.
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications.
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity).